Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVE HEART phase 2 MTP therapy study in pediatric and AYA high-grade osteosarcoma
jRCTs031240719Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirarubicin, methotrexate and cisplatin in osteosarcoma (OS), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year disease-free survival. Started Mar 2025; status: recruiting.
02
Drugs
pirarubicinmethotrexatecisplatin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on jRCTs031240719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240719.